Technology platform development for targeted plasma metabolites in human heart failure

Clinical Proteomics

Volumn 10, Issue 1, 2013, Pages

  Chan, C Y X'avia ^a   Khan, Anjum A ^b   Choi, J H Howard ^a   Ng, C M Dominic ^a   Cadeiras, Martin ^c   Deng, Mario ^c   Ping, Peipei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Thermo Fisher Scientific   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Heart disease; Sample preparation; Targeted human plasma metabolomics

Indexed keywords

AMMONIUM BICARBONATE; BICARBONATE; FORMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; HEART FAILURE; INCUBATION; METABOLITE; METABOLOMICS; PLASMA; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN DEPLETION; RECONSTITUTION; SAMPLING; SOLVENT EFFECT; TANDEM MASS SPECTROMETRY; WORKFLOW;

EID: 84899945040     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-10-7     Document Type: Article

References (49)

1. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ: Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011, 123:933-944.
2. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL: Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009, 54:1695-1702.
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Eng J Med 2002, 347:1397-1402. (Pubitemid 35239711)
4. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350. (Pubitemid 38944258)
5. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904. (Pubitemid 37430461)
6. Cotran RS, Kumar V, Robbins SL: Robbins' Pathologic Basis of Disease. 4th edition. Philadelphia, PA: WB Saunders; 1989.
7. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P: Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994, 89:151-163. (Pubitemid 24026485)
8. Bing OH, Matsushita S, Fanburg BL, Levine HJ: Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ Res 1971, 28:234-245.
9. Averill DB, Ferrario CM, Tarazi RC, Sen S, Bajbus R: Cardiac performance in rats with renal hypertension. Circ Res 1976, 38:280-288.
10. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT: Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res 1988, 22:686-695.
11. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989, 64:1041-1050. (Pubitemid 19155774)
12. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27:341-348. (Pubitemid 23116130)
13. Dixon IM, Ju H, Jassal DS, Peterson DJ: Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 1996, 165:31-45. (Pubitemid 26421348)
14. Drexler H, Coats AJ: Explaining fatigue in congestive heart failure. Annu Rev Med 1996, 47:241-256. (Pubitemid 26138889)
15. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD: Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet 1999, 353:1838-1842. (Pubitemid 29251016)
16. Dzeja PP, Redfield MM, Burnett JC, Terzic A: Failing energetics in failing hearts. Curr Cardiol Rep 2000, 2:212-217.
17. Ashrafian H: Cardiac energetics in congestive heart failure. Circulation 2002, 105:e44-e45.
18. Ingwall JS, Weiss RG: Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004, 95:135-145. (Pubitemid 38988679)
19. Lower R: Tractatus de Corde: De Motu & Colore Sagnuinus et Chyli in Eum Tranfitu. 1st edition. London, UK: Jacobi Alleftry; 1669.
20. Yndestad A, Holm AM, Muller F, Simonsen S, Froland SS, Gullestad L, Aukrust P: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003, 60:141-146. (Pubitemid 38373485)
21. Conraads VM, Bosmans JM, Schuerwegh AJ, Goovaerts I, De Clerck LS, Stevens WJ, Bridts CH, Vrints CJ: Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. J Heart Lung Transplant 2005, 24:854-859. (Pubitemid 40854165)
22. Oliver SG, Winson MK, Kell DB, Baganz F: Systematic functional analysis of the yeast genome. Trends Biotechnol 1998, 16:373-378. (Pubitemid 28410425)
23. Tweeddale H, Notley-McRobb L, Ferenci T: Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. J Bacteriol 1998, 180:5109-5116. (Pubitemid 28470937)
24. Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
25. Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L: Metabolite profiling for plant functional genomics. Nat Biotechnol 2000, 18:1157-1161.
26. Lewis GD, Gerszten RE: Toward metabolomic signatures of cardiovascular disease. Circ Cardiovasc Genet 2010, 3:119-121.
27. Waterman CL, Kian-Kai C, Griffin JL: Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim Biophys Acta 1801, 2010:230-234.
28. Griffin JL, Atherton H, Shockcor J, Atzori L: Metabolomics as a tool for cardiac research. Nat Rev Cardiol 2011, 8:630-643.
29. Rhee EP, Gerszten RE: Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58:139-147.
30. Senn T, Hazen SL, Tang WH: Translating metabolomics to cardiovascular biomarkers. Prog Cardiovasc Dis 2012, 55:70-76.
31. Turer AT: Using metabolomics to assess myocardial metabolism and energetics in heart failure. J Mol Cell Cardiol 2013, 55:12-18.
32. Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R: Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007, 8:1243-1266. (Pubitemid 47578232)
33. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM: Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008, 48:653-683. (Pubitemid 351738167)
34. Goonewardena SN, Prevette LE, Desai AA: Metabolomics and atherosclerosis. Curr Atheroscler Rep 2010, 12:267-272.
35. Mayr M, Liem D, Zhang J, Li X, Avliyakulov NK, Yang JI, Young G, Vondriska TM, Ladroue C, Madhu B, Griffiths JR, Gomes A, Xu Q, Ping P: Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J Mol Cell Cardiol 2009, 46:268-277.
36. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, Wilson ID, Kell DB, Goodacre R, Human Serum Metabolome C: Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6:1060-1083.
37. Gilstrap LG, Wang TJ: Biomarkers and cardiovascular risk assessment for primary prevention: An update. Clin Chem 2012, 58:72-82.
38. Vallejo M, Garcia A, Tunon J, Garcia-Martinez D, Angulo S, Martin-Ventura JL, Blanco-Colio LM, Almeida P, Egido J, Barbas C: Plasma fingerprinting with GCMS in acute coronary syndrome. Anal Bioanal Chem 2009, 394:1517-1524.
39. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875. (Pubitemid 43739484)
40. Dunn WB, Broadhurst DI, Deepak SM, Buch MH, McDowell G, Spasic I, Ellis DI, Brooks N, Kell DB, Neyses L: Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2- oxoglutarate. Metabolomics 2007, 3:413-426. (Pubitemid 350107675)
41. Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE: Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008, 118:3503-3512.
42. Alexander D, Lombardi R, Rodriguez G, Mitchell MM, Marian AJ: Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest 2011, 41:527-538.
43. Teul J, Ruperez FJ, Garcia A, Vaysse J, Balayssac S, Gilard V, Malet-Martino M, Martin-Ventura JL, Blanco-Colio LM, Tunon J, Egido J, Barbas C: Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J Proteome Res 2009, 8:5580-5589.
44. Yap IK, Brown IJ, Chan Q, Wijeyesekera A, Garcia-Perez I, Bictash M, Loo RL, Chadeau-Hyam M, Ebbels T, De Iorio M, Maibaum E, Zhao L, Kesteloot H, Daviglus ML, Stamler J, Nicholson JK, Elliott P, Holmes E: Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J Proteome Res 2010, 9:6647-6654.
45. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL: Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 2009, 53:2061-2067.
46. Want EJ, O'Maille G, Smith CA, Brandon TR, Uritboonthai W, Qin C, Trauger SA, Siuzdak G: Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem 2006, 78:743-752. (Pubitemid 43228581)
47. Zelena E, Dunn WB, Broadhurst D, Francis-McIntyre S, Carroll KM, Begley P, O'Hagan S, Knowles JD, Halsall A, Consortium H, Wilson ID, Kell DB: Development of a robust and repeatable UPLC-MS method for the longterm metabolomic study of human serum. Anal Chem 2009, 81:1357-1364.
48. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E: Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009, 81:6656-6667.
49. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A: HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res 2013, 41:D801-D807.